---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-25-000096"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:32:01.919501+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte Q2 net loss $166.6M, cash $2.83B; VAX-31 Phase 3 on track for Q4 start

## Summary
- Net loss $166.6M for Q2 2025 vs $128.7M a year ago; R&D expenses $194.2M, up from $131.5M.
- Cash, cash equivalents and investments $2.83B as of June 30, 2025; cash runway extended to mid-2028.
- VAX-31 adult pivotal non-inferiority study to begin Q4 2025 with topline data expected in 2026.
- VAX-31 infant Phase 2 modified: new optimized dose arm added, low dose arm discontinued; data by H1 2027.
- Early pipeline streamlined: paused VAX-A1 and VAX-GI, discontinued VAX-PG due to insufficient efficacy.

## SEC filing metadata
- accession: 0001649094-25-000096
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/0001649094-25-000096-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-25-000096
- JSON: https://secwatch.observer/filing/0001649094-25-000096.json
- Plain text: https://secwatch.observer/filing/0001649094-25-000096.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.